Illumina continues trek into drug discovery, inks AI pact with AstraZeneca
As it continues to fight for its merger with Grail, an early-detection cancer test company, the sequencing behemoth Illumina is making another push into drug development.
Tuesday morning, Illumina and AstraZeneca announced a partnership for AI drug discovery. Illumina will pitch in two AI tools — PrimateAI, which predicts diseases from mutations using primate data, and SpliceAI, which predicts how pre-mRNA sequences are cut. AstraZeneca brings its own set of AI tools, including JARVIS, which looks at non-coding genes. The initial phase of the collaboration is set to go for six months, after which “the two companies will assess opportunities for a long-term partnership,” Illumina’s chief strategy officer Joydeep Goswami told Endpoints News in an email.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.